- Conditions
- Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
- Interventions
- Not listed
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 6 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Condition Directory
Duchenne Muscular Dystrophy clinical trials
Directory of U.S. ClinicalTrials.gov public records for Duchenne Muscular Dystrophy. Browse Duchenne Muscular Dystrophy recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 24, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
12
Shown on this page
12
Current sort
Recently updated
Condition scope
Duchenne Muscular Dystrophy
Additional filters apply within this condition.
How Duchenne Muscular Dystrophy studies are organized in the registry
Duchenne records are often titled with just “Duchenne” or the abbreviation DMD, and much of the portfolio is organized around a therapeutic platform — gene transfer, exon skipping — which appears in titles. Because Duchenne is diagnosed in childhood, the age filter meaningfully changes what you see.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 13–24 of 12 matching trials for Duchenne Muscular Dystrophy.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
- Interventions
- Deramiocel (CAP-1002), Placebo
- Biological
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
- Conditions
- Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD)
- Interventions
- Zeleciment Rostudirsen (DYNE-251), Placebo
- Drug
- Lead sponsor
- Dyne Therapeutics
- Industry
- Eligibility
- 4 Years to 18 Years · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Hillsborough, North Carolina
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, placebo
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Satralizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 8 Years to 17 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Sacramento, California • Atlanta, Georgia + 3 more
- Conditions
- Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMD
- Interventions
- Tadalafil, Placebo, Exercise Training
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 6 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 0 Days to 3 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Delandistrogene Moxeparvovec, Standard of Care
- Genetic · Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 22 more
- Conditions
- Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Boston, Massachusetts • New York, New York
- Conditions
- Duchenne Muscular Dystrophy (DMD), Becker's Muscular Dystrophy (BMD)
- Interventions
- Descending stair walk
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 10 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- No Intervention
- Genetic
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 2 more
About this Duchenne Muscular Dystrophy clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Duchenne Muscular Dystrophy as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Duchenne Muscular Dystrophy.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Duchenne Muscular Dystrophy.